In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Relypsa brings in $70mm through its Series B venture round

Executive Summary

Relypsa Inc. (developing nonabsorbed polymeric therapeutics for cardiovascular and renal conditions) has raised $70mm through the closing of its Series B venture round. New investor OrbiMed Advisors led the financing (and contributes a board member) and was joined by current shareholders New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group, and Mediphase Venture Partners. The company will use the funds to continue working on RLY5016, which has finished Phase II for chronic and acute hyperkalemia, a disease prevalent in patients with renal impairment, hypertension, diabetes, and heart failure.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies